One of these reports , the joint analysis of North Central Cancer Treatment Group NCCTG N9831 ( Combination Chemotherapy With or Without Trastuzumab in Treating Women With HER2-Overexpressing Breast Cancer ) and the National Surgical Adjuvant Breast and Bowel Project NSABP B-31 ( Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 ) , was updated in 2011 .